

Supplementary Table 1. Number needed to treat (NNT) for ACR response at weeks 12–16 and week 24 among bDMARD-naïve patients with active PsA (placebo as reference)

Treatment ^a	ACR20		ACR50		ACR70	
	Posterior median values (95% credible interval)					
	Weeks 12-16	Week 24	Weeks 12-16	Week 24	Weeks 12-16	Week 24
Abatacept 10 mg/kg Q4W IV	5.63 (-26.59, 47.10)	3.14 (1.72, 13.29)	9.82 (-57.70, 95.63)	4.16 (1.92, 20.77)	22.68 (-163.51, 257.79)	6.91 (2.59, 41.15)
Abatacept 125 mg SC	9.57 (-86.03, 110.83)	5.88 (3.06, 23.72)	17.94 (-181.59, 230.60)	8.64 (4.06, 38.03)	44.37 (-508.87, 624.33)	16.07 (6.70, 77.56)
Adalimumab 40 mg Q2W	2.96 (2.48, 3.66)	2.62 (2.17, 3.35)	4.46 (3.53, 5.84)	3.34 (2.61, 4.50)	8.88 (6.59, 12.42)	5.28 (3.88, 7.59)
Apremilast 30 mg BID	5.48 (4.08, 8.17)	4.16 (3.04, 6.49)	9.51 (6.69, 15.03)	5.82 (4.01, 9.61)	21.88 (14.41, 36.74)	10.25 (6.59, 18.10)
Certolizumab pegol pooled doses ^b	3.57 (2.56, 5.86)	2.96 (2.23, 4.38)	5.68 (3.68, 10.28)	3.87 (2.73, 6.17)	11.94 (6.94, 23.98)	6.33 (4.09, 10.99)
Etanercept 25 mg BIW/50 mg QIW	2.04 (1.68, 2.69)	3.07 (2.09, 5.90)	2.68 (2.01, 3.90)	4.05 (2.51, 8.61)	4.60 (3.09, 7.54)	6.68 (3.68, 15.90)
Golimumab 50 mg Q4W	1.94 (1.58, 2.62)	2.19 (1.74, 3.06)	2.48 (1.81, 3.77)	2.65 (1.94, 4.01)	4.14 (2.65, 7.19)	3.95 (2.62, 6.59)
Infliximab 5 mg/kg Q8W	1.83 (1.56, 2.27)	2.18 (1.72, 3.12)	2.27 (1.77, 3.11)	2.63 (1.91, 4.12)	3.66 (2.57, 5.61)	3.91 (2.56, 6.82)
Ixekizumab 80 mg Q2W	2.71 (2.11, 3.87)	2.46 (1.95, 3.43)	3.97 (2.81, 6.26)	3.07 (2.27, 4.61)	7.68 (4.88, 13.47)	4.76 (3.23, 7.79)
Ixekizumab 80 mg Q4W	3.04 (2.28, 4.59)	3.04 (2.27, 4.67)	4.62 (3.13, 7.69)	4.01 (2.78, 6.63)	9.27 (5.65, 17.13)	6.61 (4.20, 11.92)
Secukinumab 150 mg Q4W	3.60 (2.95, 4.61)	2.80 (2.34, 3.50)	5.73 (4.44, 7.73)	3.62 (2.89, 4.73)	12.07 (8.74, 17.36)	5.85 (4.41, 8.06)
Secukinumab 300 mg Q4W	2.97 (2.49, 3.68)	2.48 (2.13, 3.00)	4.48 (3.54, 5.89)	3.11 (2.56, 3.94)	8.95 (6.60, 12.60)	4.84 (3.77, 6.46)
Tofacitinib 5 mg BID	3.97 (2.76, 6.89)	3.06 (2.09, 5.93)	6.46 (4.06, 12.41)	4.05 (2.49, 8.69)	13.93 (7.89, 29.56)	6.68 (3.64, 16.19)
Ustekinumab 45 mg Q12W	5.18 (3.51, 9.35)	4.82 (3.39, 8.02)	8.92 (5.56, 17.41)	6.90 (4.57, 12.11)	20.31 (11.56, 43.16)	12.45 (7.72, 23.35)
Ustekinumab 90 mg Q12W	5.42 (3.64, 9.99)	3.89 (2.90, 5.81)	9.41 (5.80, 18.76)	5.39 (3.80, 8.52)	21.58 (12.15, 46.68)	9.38 (6.18, 15.81)

^aMixed biologic-naïve and -experienced population for the following treatments: abatacept 10 mg/kg Q4W IV, secukinumab 150 mg Q4W, secukinumab 300 mg Q4W and placebo; ^bCertolizumab pegol pooled doses are 200 mg Q2W and 400 mg Q4W

ACR20, 50, 70 = minimum of 20%, 50% and 70% improvement from baseline in American College of Rheumatology (ACR) score; bDMARD = biologic disease-modifying antirheumatic drug; BID = twice daily; BIW = twice weekly; IV = intravenously; PsA = psoriatic arthritis; QIW = once weekly; QxW = every x weeks; SC = subcutaneously